Instructions and definitions available here. Frequently asked questions available here.

New Study Checklist

Study Title:	
Sponsor (if applicable):	
Investigator:	
CRA:	
Coordinator:	
Financial Manager:	
IRB#:	

Item	Yes	No	N/A	Date Received	Date Completed	Comments				
STUDY ID / GENERAL INFORMATION										
Is your study industry or foundation sponsored*?										
Is your study government (NIH, DOD, CDD, etc.) sponsored?										
Is your study intramurally sponsored (Alliance, COM, Department, CCTS, etc.)?										
A service request form is required if utilizing CCTS s	Center for Clinical and Translational Science (CCTS) (if applicable) A service request form is required if utilizing CCTS services (http://www.ccts.uky.edu/ccts/ccts-service-request-forms). The CCTS will contact you and provide a budget estimate and letter of agreement. These must be executed prior to initiation of services.									
Budget estimate and letter of agreement executed with CCTS?										
Cancer Patients (if applicable)	Cancer Patients (if applicable)									
Does the study involve enrolling cancer patients? If so, contact the Markey Cancer Center Research Network at (859) 218-4062.										
Has Markey Cancer Center approval been received?										

^{*} Only required if your study is industry sponsored

				Date	Date	
Item	Yes	No	N/A	Received	Completed	Comments

SPACE / LABORATORIES / SITE INFORMATION									
Site Selection and Initiation*									
Has the site selection visit been completed?									
Has the site selection letter been received?									
Is UK Healthcare Ambulatory space being used to conduct research participant evaluations?									
If yes, are room fees applicable for the use of this space?									
If yes, have the room fees been included in the budget?									
Veteran's Affairs (VA) Patients (if applicable)								
Does the study involve enrolling patients from the VA? If so, contact the VA for additional information regarding research.									
Has VA approval been received?									
Laboratories									
Are UK Healthcare laboratories being used?									
Are any outside laboratories being used?									
Are all laboratories **CAP/CLIA certified?									
Will outside laboratory results be entered into Epic?									
If the study uses test results from a non-CLIA certified laboratory, do you agree that the									
results will not be used to guide clinical care? External Sites (if applicable) This applies to res Contact UK College of Medicine Office of Research									
Does your study involve an external site?									

^{*} Only required if your study is industry sponsored

** College of American Pathologists (CAP) and Clinical Laboratory Improvement Act (CLIA)

Item	Yes	No	N/A	Date Received	Date Completed	Comments				
Does the external site's contract with UK allow research?										
Has indemnification of the external site been addressed?										
Will data be shared between the sites?										
Home Health Exemption (if applicable)	Home Health Exemption (if applicable)									
Does the study involve going into a patient/participant's home? If so, you may need a home health exemption. Contact UK Office of Legal Counsel at ukofficeoflegalcounsel@uky.edu for assistance. Has a Home Health Exemption been received?										
COI / CDA / NDA / MTA / DUA										
Conflict of Interest (COI) Pls are responsible for ensuring that significant financial interests and potential COIs are appropriately disclosed in IRB applications and any other required disclosure forms not vetted by the institution (e.g. FDA FCOI forms).										
Has the Office of Sponsored Projects Administration (OSPA) been contacted for COI disclosures, https://www.research.uky.edu/office-sponsored-projects-administration/conflict-interest ?										
Confidentiality Agreement (CDA/NDA)* Most sponsors require a signed confidentiality agreement prior to sharing a protocol. PIs are not authorized to sign CDAs. The Office of Technology and Commercialization has sole signatory authority. Information on where to send draft CDAs can be found at https://www.research.uky.edu/office-technology-commercialization/transfer-agreements .										
Fully executed CDA received?										
Clinical Trial Agreement (CTA)* CTAs are negotiated by the Office of Sponsored Pro	ojects A	\ <u>dmin</u> i	stratior	n (OSPA). PIs can	not sign CTAs. OS	PA has sole signatory authority.				
Fully executed CTA?										

^{*} Only required if your study is industry sponsored

Item	Yes	No	N/A	Date Received	Date Completed	Comments				
Non-Indemnification It is the responsibility of the principal investigator to initiate the non-indemnification review process for all eligible clinical trials, as defined here. If an investigator does not forward a study for review that qualifies for Inclusion in the Indemnification Process and a problem occurs and a claim is made, the University is not obligated to defend the investigator. Contact (859) 218-6610 with any questions regarding the non-indemnification submission/review process. If your agreement is industry/externally sponsored, please contact OSPA if you have questions about whether your study qualifies for non-indemnification review.										
Have you contacted UK Healthcare Risk Management Committee about non-indemnification review?										
Data/Material Sharing Information can be found at https://www.research.uk contact information regarding data/material sharing.		office-	<u>techno</u>	logy-commercializ	ation/transfer-agre	ements including appropriate				
Is the study sharing confidential information outside of UK and/or is UK receiving confidential information from outside UK?										
Material Transfer Agreement (MTA) Information can be found at https://www.research.uky.edu/office-technology-commercialization/transfer-agreements including appropriate contact information regarding MTAs.										
Will you be transferring materials (specimens, cell lines, mice, plants, etc.) outside of UK?										
If so, has an MTA been executed? Will you be transferring data (fully deidentified, a limited data set, or Protected Health Information (PHI)/Personally Identifiable Information (PII)) outside of the University?										
If yes, has a Data Use Agreement (DUA) been executed?										
If yes, did the DUA describe data destruction guidance?										
If no, is the data set a limited data set?										
If no, is the data set de-identified? Will the data be stored at UKHC?										

						1				
				Date	Date					
Item	Yes	No	N/A	Received	Completed	Comments				
If yes, has the request been reviewed by										
UKHC IT to determine if technology resources										
are required to support data storage?										
BUDGET / Co	OVER	RAGE	E ANA	ALYSIS / BILL	ING REVIEW					
Sponsor Budget Development/Negotiation*										
Sponsors will typically send a budget template to guide budget negotiations. The budget should always be prepared using actual costs.										
Along with patient care costs, o PI effort, coordinato										
stipend, long-term storage costs, IRB fees, pass-thru costs (protocol amendments, SAEs, IND safety reports, protocol violations, etc), and indirect costs need to be included.										
The F&A rate for indirect costs is determined by OSPA. Guidelines for F&A can be found here; any questions about the appropriate F&A rate										
should be directed to OSPA.	1 A. O	ilaciii i	03 101 1	AA Can be lound	nere, any question	s about the appropriate r &A rate				
Sponsor budget approved?										
eIAF completed?										
https://www.research.uky.edu/uploads/instructi										
ons-completing-eiaf-myuk										
Coverage Analysis and Billing Review	ot: btt	no://oc	todata	uky odu/momboro	hin/					
Submit a service request form for coverage analysis Has the study been submitted to the CRSO	а а. <u>пц</u>	05.//60	isuala.	uky.eau/members	<u>ariip/</u>	T				
MCA team for review?										
Did the MCA team determine if the study is										
qualifying?										
Billing Review: If a Clinical Research study con-	tains it	ems a	and se	rvices provided a	nt any UKHC facil	lity or by UKHC providers (i.e.,				
Labs, Scans, Examinations), the research study										
segregation.					·	_				
A clinical research study (clinical trial or research	h with	billab	le iten	ns) must be in the	e CTMS system a	and is send to the EHR (Epic)				
system after the billing review or CA has been completed.										
Do you have a designated staff member who										
reviews the billing in Epic and maintains the										
records in the CTMS system?										

^{*} Only required if your study is industry sponsored

Item	Yes	No	N/A	Date Received	Date Completed	Comments				
OnCore All studies meeting the NIH definition of a clinical trial need to be built into Oncore regardless of the sponsor. To review the NIH definition of a clinical trial go to https://grants.nih.gov/policy/clinical-trials/definition.htm .										
Does the study need to be built into OnCore? Please contact CRSOStudyAssist@uky.edu with any questions.										
Has the study been built in OnCore? Please submit studies at https://www.research.uky.edu/clinical-										
research-support-office										
Epic										
After the Billing review or CA process - Does										
the study have any services or procedures										
that will occur at a designated UKHC facility or										
provided by any UKHC provider? If so, the										
study must be included in Epic. If you have										
questions about this process please contact										
the CRSO at CRSOStudyAssist@uky.edu										
INVESTIGATIONA	L DR	UG /	DEV	ICE AND REL	ATED SERVI	CES				
Investigational Drug Studies and IDS-related	l servi	ces (i	f appl	icable)						
Does the study use an investigational drug? If										
yes, contact IDS@uky.edu to request IDS										
support and agreement that support will be										
provided per the study protocol.										
If your study includes an investigational drug,										
have you obtained the FDA approval? A										
treatment could be a drug, medical device, or										
biologic, such as a vaccine, blood product, or										
gene therapy. Drug developers, or sponsors,										
must submit an Investigational New Drug										
(IND) application to FDA before beginning										
clinical research.										

Item	Yes	No	N/A	Date Received	Date Completed	Comments		
Do you need an IND based on the FDA rules? There are three IND types: An Investigator IND, Emergency Use IND (21CFR, Sec. 312.23 or Sec. 312.20), AND Treatment IND is submitted for experimental drugs showing promise in clinical testing for serious or immediately life-threatening conditions. There are two IND categories: Commercial & Research (non-commercial)								
If your study is exempt, please document it as set forth by the FDA regulations: To be exempt [21 CFR 312.2(b)], 1) the drug must be lawfully marketed in the US, 2) the study cannot be intended to support a new indication or other significant change in product labeling, 3) the study cannot be intended to support a significant change in advertising for the drug or be used to promote the drug. During the billing review and study submission to the CRSO please indicate if your study is IND exempt.								
Is IDS providing support for your study?								
Device Studies (if applicable)	1 1				I			
Does your study involve a device? If so, you may need to go through the Celerian Group Company (CGS) device notification process. Contact renee.hensley@uky.edu (Please note this will require annual reapproval)								
CMS approval needed for: Studies with the Category A are approved for coverage of routine services only. Studies with the Category B are approved for coverage of the Category B device and related services, and routine services.								

If your study is NOT submitted and approved under the CMS guidelines, the study is considered to be Non-Qualifying for coverage of routine costs under the CMS NCD 310.1. You can still conduct your study but the coverage by insurances will be limited.

Ensure that you (your sponsor) follows the FDA requirements for Medical devices are classified into Class I, II, and III. Regulatory control increases from Class I to Class III. The device classification regulation defines the regulatory requirements for a general device type. Most Class I devices are exempt from Premarket Notification 510(k); most Class II devices require Premarket Notification 510(k); and most Class

				Date	Date					
Item	Yes	No	N/A	Received	Completed	Comments				
		ı		1						
III devices require Premarket Approval. A description "Classification of Medical Devices."	n of de	vice c	lassifica	ation and a link to	the Product Classi	ification Database is available at				
Have you received approval for use of your research device at UK?										
Does your device need engineering review?										
REGULATORY										
Certificate of Confidentiality										
All NIH sponsored clinical trials automatically fall under a certificate of confidentiality if needed per the study protocol. Studies not sponsored										
by the NIH must request a certificate of confidential				ore information go	to https://www.res	earch.uky.edu/uploads/ori-				
d560000-certificate-confidentiality-frequently-asked	<u>-questic</u>	ons-ta	<u>qs-pdf</u> .	T	1					
Does your study have a certificate of										
confidentiality?										
If yes and data is entered into Epic, is a										
system in place to assure confidentiality?	<u></u>									
Institutional Review Board (IRB)										
If your study involves human subjects either IRB ap	proval	or an I	RB wa	iver must be obtail	ned.	T				
Are you using the UK IRB?										
Are you using a central IRB?										
If a central IRB, do you have a reliance										
agreement in place?										
Has IRB approval been received?										
Clinical Trials.gov	Clinical Trials.gov									
Does your study need to be registered on										
ClinicalTrials.gov? If you have any questions										
about ClinicalTrials.gov, please contact <u>UK's</u>										
Clinical Trials Compliance Administrator.										
If yes, what is the assigned NCT number										
(found within your ct.gov account)?										

Item	Yes	No	N/A	Date Received	Date Completed	Comments				
Institutional Biosafety (IBC) (if applicable)										
Does the study need to be registered with the										
Institutional Biosafety Committee (IBC)? For										
more information, http://ehs.uky.edu/docs/pdf/bio_ibc_registratio										
n 0001.pdf										
Has IBC approval been received?										
Radioactive Material										
Does your study involve the procurement, use,										
storage and disposal of radioactive material										
and radiation-producing devices? If yes, visit										
https://www.research.uky.edu/office-research-										
integrity/irb-application-instructions-radiation-										
safety for more information.										
Biobanking										
Will any biobanking be done as part of the research?										
If yes, has biobanking language been included in the consent?										
Genetic Testing										
Will any genetic testing be performed?										
If yes, has genetic testing language been										
included in your consent?										
		7	RAIN	IING						
Human Subject's Protection (HSP) All key personnel working on studies involving huma	an cubi	acts m	ust co	mnlete HSD trainir	na https://www.roo	earch uky edu/office research				
integrity/human-subject-protection-hsp-training-fags		-cis III	usi coi	iipiele i ior liallill	ig. <u>mups.//www.fes</u>	earch.uny.euu/omce-research-				
Have all key personnel completed HSP										
training?										

lta ma	V	NI.	NI/A	Date	Date	Community				
Item	Yes	No	N/A	Received	Completed	Comments				
Responsible Conduct of Research (RCR)										
All full-time faculty, staff, graduate students, and trainees (undergraduates, postdoctoral fellows, visiting scientists) who participate in										
research or creative work, including individuals supported in part or fully through research funding, grants, or contracts are required to										
complete the Responsible Conduct of Research (RCR) course initially and then every 2 years.										
Have all required key personnel completed										
RCR training?										
Good Clinical Practice (GCP) (if applicable)										
Individuals who are conducting research trials for drugs, biologics or devices should complete GCP training. GCP training is required for all										
NIH-sponsored studies and/or if you are using any	CCTS 8	ervice	S.	T	1					
Have all required key personnel completed										
GCP training?										
DOT/IATA (if applicable)										
The University requires all faculty, staff and student		are inv	olved i	n any aspect of sh	ipping dangerous	goods (e.g., packing, labeling,				
transporting, etc.) to attend a DOT/IATA Initial Train	ing									
course.										
The initial course is held in a classroom setting so c			mited a	nd pre-registratior	n is required. Regis	ster at				
https://ehs.uky.edu/classes/classes env 0001.php	<u>‡dot ia</u>	<u>ta</u> .		T	1					
Have all staff shipping dangerous goods										
completed DOT/IATA training?										
Institutional Biosafety (IBC) (if applicable)										
https://ehs.uky.edu/classes/										
Have all required key personnel completed										
IBC training?										